טוען...
Insights Into the Mechanism of OnabotulinumtoxinA in Chronic Migraine
OnabotulinumtoxinA has recently been approved by regulatory agencies in the UK and United States for treatment of chronic migraine based on data generated from the PREEMPT studies. As such, onabotulinumtoxinA is the only prophylactic therapy specifically approved for chronic migraine. Most headache...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3306767/ https://ncbi.nlm.nih.gov/pubmed/22082429 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1526-4610.2011.02022.x |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|